Applied Biosciences Corp. (APPB)

[NYOptionsGuy]

Stony Hill (STNY:OTC) adds to advisory board as advisor-linked company makes moves

Source: https://equity.guru/2017/12/15/stony-hill-stnyotc-adds-advisory-board-advisor-linked-company-makes-moves/

Sometimes when a public company is being quiet, the only way to figure out what they’re up to is to connect dots and assess risk. Stony Hill Corporation (STNY.OTC) is one company in that category.

The US-based weed play, with music star and Jay-Z support act Damian “Jr Gong” Marley at the helm, has a low profile, especially among Canadian investors, as it quietly grabbed a piece of the recent $70 million High Times Magazine acquisition, opened a Colorado dispensary, and has gathered a group of advisors that have serious pharma background.

The star power of its Bob Marley-bred director notwithstanding, who named his recent hit album after the company, Stony Hill isn’t what you might expect of an OTC weed play. It doesn’t claim billions in future revenues, it doesn’t so weird deals with weird companies designed to crank a market cap. It acts like a vertical integrator, snapping up assets without fanfare, putting together a puzzle that will only become clear when it’s done.

While I can appreciate a lack of over-hype and false promises, my struggle with STNY, and the reason it has traded lightly, is that it’s moving silently, like a submarine stalking destroyers, while the market (especially the OTC) obviously loves a loudmouth.

It’s an odd thing for an OTC play, especially one in weed, to not blurt out a million promises to anyone who’ll listen, but STNY has been especially stingy with its news. Indeed, when it added to its advisory board recently, there was no news release announcing it, though the addition was a solid one.

Dr Raymond Urbanski is the is Chief Medical Officer at GT Biopharma, the $250 million NASDAQ pharma group that is focused on “targeting multiple myeloma, triple-negative breast cancer, non-Hodgkin’s lymphoma and more with highly potent biopharmaceutical drugs designed for targeted therapy.”

Urbanski oversees the development of products in the GTBP pipeline so, my first thought, when I saw this addition on the Stony Hill bio pages, was, “Ah ha! Is there a GTBP-STNY connection coming?”

If there was, it would explain why STNY is so quiet. When you’re doing a deal with a bigger player, you kind of shut the hell up until the ink is dry on a deal. But I couldn’t find any indication there was anything going on there.

So I looked deeper.

“Previously, he served as Chief Medical Officer and Senior Director of oncology research and development at Pfizer Inc. (PFE:NYSE).

Holy crap! A Pfizer connection would be lights out on this stock, if there were any indication of a deal in place. But, nothing I could find there either.

Deeper still.

He served as CMO of Mylan Inc, Senior Director of US Medical Affairs for AventisCMO at Cymabay Therapeutics/Metabolex, CMO and VP for Research and Development at Suntory Pharmaceutical, he’s been at Aventis and AstraZeneca… It’s a hell of a resume.

But there was one connection that made me seriously think about possibilities.

Urbanski only recently joined GTBP, but previously served as the Chief Medical Officer of MannKind Corp. from 2015 until recently, as its Corporate Vice President.

From his bio, “Dr. Urbanski led MannKind’s overall drug development activities and is a member of the Executive Leadership Team.”

So let’s go see what Mannkind has been up to recently.

REST OF ARTICLE: https://equity.guru/2017/12/15/stony-hill-stnyotc-adds-advisory-board-advisor-linked-company-makes-moves/